India’s Contract Analysis, Growth, and Manufacturing Group (CRDMO) sector is poised for a transformative leap, with projections indicating an enlargement from its present valuation of $3–3.5 billion to a sturdy $22–25 billion by 2035.
This development trajectory is detailed within the Unleashing the Tiger: Indian CRDMO Sector 2025, printed by Boston Consulting Group (BCG) in collaboration with the Modern Pharmaceutical Companies Organisation (IPSO).
The Indian CRDMO business has demonstrated a compound annual development charge (CAGR) of 15% from 2019 to 2024, surpassing the worldwide common of seven–8%. This momentum is additional fueled by international provide chain realignments, with Western pharmaceutical firms in search of alternate options to conventional hubs like China. Such shifts current India with a big alternative to grow to be a most popular outsourcing vacation spot, unlocking an estimated $10–15 billion in potential worth.
Nevertheless, to totally capitalize on these alternatives, the sector should tackle a number of important challenges. Key amongst them is the necessity to scale the workforce by 6–7 instances by 2035, guaranteeing a gentle provide of expert expertise. Moreover, streamlining regulatory processes to cut back approval timelines, enhancing home manufacturing of important uncooked supplies, and fostering a sturdy Tier-1 provider ecosystem are crucial steps.
The report additionally emphasizes the significance of advancing in biologics and new modalities, akin to gene therapies and RNA-based remedies, to take care of competitiveness. Listed here are the CRDMO shares to maintain in your radar.
In late September 2025, the U.S. launched a one hundred pc tariff on branded and patented drug imports, creating short-term uncertainties for Indian pharmaceutical exporters, particularly these specializing in complicated generics and biologics.
Whereas this poses challenges, it could additionally speed up the adoption of cheaper alternate options, providing a possible increase to India’s generics and CRDMO (Contract Analysis, Growth, and Manufacturing Group) sectors within the close to time period.
In response to the BCG-IPSO report, India’s CRDMOs profit from a big price benefit, with workforce bills 70–80 % decrease and infrastructure setup prices roughly 85% cheaper than in Western nations. Quicker venture startup instances and stronger mental property protections additional improve India’s enchantment as a most popular outsourcing vacation spot.
Moreover, firms which might be establishing manufacturing services within the U.S. are exempt from the tariff, offering a transparent pathway to mitigate potential dangers. Many Indian CRDMOs are already increasing their presence within the U.S., U.Ok., and Europe, positioning themselves as dependable international companions and capitalizing on alternatives within the worldwide pharmaceutical market.
Additionally learn: Largecap energy inventory to purchase now for an upside of greater than 30%; Do you personal it?
Divis Laboratories Restricted is a Hyderabad-based pharmaceutical firm engaged within the manufacture and sale of generic energetic pharmaceutical elements (APIs), intermediates, and nutraceuticals throughout India, North America, Europe, Asia, and different worldwide markets.
The corporate additionally gives customized synthesis contract manufacturing of APIs and intermediates, and produces carotenoids akin to beta carotene, astaxanthin, lycopene, canthaxanthin, lutein, and nutritional vitamins for the meals, beverage, dietary complement, pet meals, and feed industries. Included in 1990 and renamed Divi’s Laboratories Restricted in 1994, it continues to increase its international footprint. The corporate has a market cap of Rs. 1,74,885.39 crore and a present market worth of Rs. 6,587.80.
Syngene Worldwide Ltd is an built-in analysis, improvement, and manufacturing providers firm serving the pharmaceutical, biotechnology, vitamin, animal well being, client items, and specialty chemical compounds sectors.
With over 5,600 scientists and greater than 2.5 million sq. ft of specialised discovery, improvement, and manufacturing services, the corporate collaborates with round 400 international purchasers, together with multinationals like BMS, GSK, Zoetis, and Merck KGaA. Syngene focuses on accelerating innovation whereas guaranteeing information safety and high-quality output. The corporate has a market cap of Rs. 26,610.12 crore and a present market worth of Rs. 660.40.
Laurus Labs is a research-driven pharmaceutical and biotechnology firm specializing within the improvement and manufacture of choose APIs and completed dosage kinds throughout anti-retroviral, oncology, cardiovascular, and gastrointestinal therapies.
The corporate gives end-to-end CDMO providers and is thought for its sturdy backward integration, high-quality requirements, and sustainable “Good and Inexperienced” chemistry strategy. Using over 7,000 professionals, together with greater than 2,600 scientists, Laurus operates 15 international regulatory-approved services. Its market cap stands at Rs. 49,947.30 crore and its present market worth is Rs. 925.25.
Piramal Pharma Restricted affords a diversified portfolio by way of its international improvement and manufacturing community, spanning 17 services throughout 100+ nations. The corporate operates Piramal Pharma Options (CDMO providers), Piramal Important Care (complicated hospital generics), and Piramal Shopper Healthcare (OTC wellness merchandise), together with strategic partnerships akin to Abbvie Therapeutics India Non-public Restricted. It additionally invests in biologics and vaccines by way of Yapan Bio Non-public Restricted. Piramal Pharma has a market cap of Rs. 26,884.04 crore and a present market worth of Rs. 202.25.
Suven Life Sciences Restricted is targeted on the invention and scientific improvement of modern therapies focusing on central nervous system (CNS) issues. The corporate has superior scientific candidates for Alzheimer’s illness, sleep issues, main depressive dysfunction, Parkinson’s illness, schizophrenia, ache issues, and gastrointestinal issues, whereas sustaining seven further initiatives in its analysis pipeline. Suven owns mental property rights for all its belongings globally. The corporate has a market cap of Rs. 4,539.25 crore and a present market worth of Rs. 199.55.
Jubilant Pharmova Restricted operates throughout Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, generics, and proprietary novel medicine. With a worldwide presence, the corporate manufactures and provides radiopharmaceuticals within the US, allergy merchandise throughout a number of markets, and sterile injectable formulations.
Its CRDMO providers embrace drug discovery, API manufacturing, and proprietary drug improvement, supported by 5,500 workers worldwide. Jubilant Pharmova has a market cap of Rs. 17,810.82 crore and a present market worth of Rs. 1,118.20.
Cohance Lifesciences, previously Suven Prescribed drugs, is a worldwide CRDMO delivering built-in options from early improvement to industrial provide for main pharma firms. With state-of-the-art services in India and the US, Cohance leverages its platform to offer modern providers for international purchasers. In FY25, the corporate generated revenues of Rs. 26 billion (USD 313 million) with an adjusted EBITDA margin of 33.6 %. The corporate has a market cap of Rs. 33,560.70 crore and a present market worth of Rs. 877.25.
Senores Prescribed drugs is a research-driven pharmaceutical firm engaged in growing and manufacturing a variety of merchandise for the US, Canada, and different regulated and rising markets. Its portfolio consists of 70 ANDA and 27 CMO/CDMO merchandise for the US, together with important care injectables and APIs.
The corporate operates manufacturing services in India (Chhatral and Naroda) and the US (Atlanta), with approvals from a number of international regulators. Senores Pharma has a market cap of Rs. 3,535.07 crore and a present market worth of Rs. 767.60.
Sai Life Sciences is a number one built-in CRDMO working with over 300 international innovator pharma and biotech firms to speed up discovery, improvement, and manufacturing of complicated small molecules. The corporate operates state-of-the-art services in India, the UK, and the US, with a robust emphasis on sustainability and effectivity, enabling quicker supply of latest medicines. Sai Life Sciences has a market cap of Rs. 18,807.97 crore and a present market worth of Rs. 896.35.
Written by – Manan Gangwar
Disclaimer
The views and funding ideas expressed by funding specialists/broking homes/ranking companies on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of monetary losses. Traders should subsequently train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Non-public Restricted or the creator are usually not answerable for any losses brought about because of the choice based mostly on this text. Please seek the advice of your funding advisor earlier than investing.
